20th International Congress » Clinical trials and therapy in movement disorders

12:00pm-1:30pm

A clinical trials ‘charter’ to improve communication about, recruitment to and retention in Parkinson’s clinical trials

C. Carroll, I. Tom, M. Helen, S. Jon (Plymouth, United Kingdom)

12:00pm-1:30pm

A crossover study of pretarsal and preseptal injections of botulinum toxin type A (BTX-A) in the treatment of hemifacial spasm and blepharospasm

A. Choolam, K. Kulkantrakorn, P. Lolekha (Pathumthani, Thailand)

12:00pm-1:30pm

A double-blind randomized controlled trial of cognitive training for freezing of gait in Parkinson’s disease

C.C. Walton, L. Mowszowski, J.M. Shine, M. Gilat, J.M. Hall, C. O'Callaghan, A.J. Muller, M. Georiades, J.Y.Y. Szeto, K.A. Ehgoetz Martens, S.L. Naismith, S.J.G. Lewis (Sydney, Australia)

12:00pm-1:30pm

A randomized clinical trial of atomoxetine treatment for mild cognitive impairment (MCI) in Parkinson’s disease (PD)

V.K. Hinson, J. Elm, A. Delambo, T. Turner (Charleston, SC, USA)

12:00pm-1:30pm

A survey of impulse control disorders in Chinese patients with Parkinson’s disease and literature review

Q. Xiao, X. Wang, Y. Tan, M. Wei (Shanghai, People's Republic of China)

12:00pm-1:30pm

Active movement discrimination of the ankle in Parkinson’s disease

H.E. Teasdale, E.A. Preston, G. Waddington (Canberra, Australia)

12:00pm-1:30pm

Applicability study of a multitask cognitive and motor exercise program for individuals with Parkinson´s disease: The COGWEB CNS Move Program

J. Domingos, D. Peralta, R. Loureiro, C. Ribeiro, V.T. Cruz, J. Ferreira (Torres Vedras, Portugal)

12:00pm-1:30pm

Apraclonidine in the treatment of ptosis

S. Wijemanne, D. Vijayakumar, J. Jankovic (Houston, TX, USA)

12:00pm-1:30pm

Are Parkinson’s disease futility studies futile?

B.C. Tilley, J. Elm (Houston, TX, USA)

12:00pm-1:30pm

Beta – blockers worsen vascular parkinsonism in patients with concomitant coronary heart disease

A. Turakhonov, S. Dadajonov, R. Sadikov, R. Khodjaev, S. Nurov (Tashkent, Uzbekistan)

12:00pm-1:30pm

Botulinum toxin in cerebral palsy children with gait disorder: Different therapy approaches

G.S. Pilina (Izhevsk, Russia)

12:00pm-1:30pm

Changes of speech after neurostimulation for Parkinson’s disease with early fluctuations: A 2-years randomized controlled trial (earlystim-speech)

S. Pinto, A. Nebel, R. Espesser, J. Rau, P. Maillochon, O. Krack, K. Knudsen, A. Ghio, O. Niebuhr, Y. Agid, M. Schüpbach, G. Deuschl (Aix-en-Provence, France)

12:00pm-1:30pm

Classification and recommendation of nonpharmacological therapies for Parkinson’s disease

T.T.C. Capato, C.H. Fen, E.R. Barbosa (São Paulo, Brazil)

12:00pm-1:30pm

Clinical benefits of vestibular rehabilitation in neurodegenerative diseases

B.S. Zeigelboim, G.B. Santos, H.A.G. Teive, M.I.R. Severiano, C.M. Porto (Curitiba, Brazil)

12:00pm-1:30pm

Cognitive behavioural thrapy and adiunctive physical therapy for functional movement disorders

R. Erro, M. Tinazzi, C. Dallocchio (London, United Kingdom)

12:00pm-1:30pm

Combined stimulation of STN and SNr for resistant freezing of gait in Parkinson’s disease (STN+SNr) – A multicenter randomized controlled trial

D. Weiss, G. Naros, C. Meisner, R. Krüger, A. Gharabaghi (Tübingen, Germany)

12:00pm-1:30pm

Detailed evaluation of dyskinesias using multiple endpoints in a randomized, placebo-controlled trial of Parkinson’s disease patients with motor fluctuations

C. Kenney, K. Kieburtz, W. Olanow, S. Bandak (San Francisco, CA, USA)

12:00pm-1:30pm

Effect of outside influences on the therapeutic benefits of botulinum toxin injections

D.C. Taylor, P.A. LeWItt, P. Kaminski (Royal Oak, MI, USA)

12:00pm-1:30pm

Effect of right DLPFC-repetitive transcranial magnetic stimulation (rTMS) on tardive dyskinesia in patients with psychosis

S. Lavania, A. Pattojoshi, A.H. Khan, S. Lavania (Agra, India)

12:00pm-1:30pm

Effects of the biodex stability system training on balance, gait and fatigue in Parkinson’s disease

G. Singh, R. Pahwa, K.E. Lyons, Y. Colgrove, N.K. Sharma (Troy, NY, USA)

12:00pm-1:30pm

Efficacy of 4845 botulinum toxin (BoNT) treatment cycles, and clinical strategies after a failed cycle

P. Tanvijit, A.P. Moore (Bangkok, Thailand)

12:00pm-1:30pm

Efficiency of carotid endarterectomy in vascular parkinsonism in patients with stenotic carotid artery disease

M. Ataniyazov, G. Rakhimbaeva, K. Ataniyazova (Tashkent, Uzbekistan)

12:00pm-1:30pm

Familial cortical myoclonic tremor with epilepsy in Chinese population: Clinical and neurophysiologic features in nine pedigrees from People’s Republic of China

Z. Cen, C. Huang, H. Yin, F. Xie, X. Lu, Z. Ouyang, Y. Lou, X. Qiu, Z. Wang, J. Xiao, M. Ding, W. Luo (Hangzhou, People's Republic of China)

12:00pm-1:30pm

Global implementation of efficacious voice treatment for Parkinson’s disease: LSVT LOUD: Germany®

T. Brauer, H. Penner, P. Benecke, C. Fox, L. Ramig (Mainz, Germany)

12:00pm-1:30pm

LSVT-BIG© case studies: A snapshot of observations

L.A. Dearle (Johannesburg, South Africa)

12:00pm-1:30pm

Neural plasticity and freezing of gait: Stepping through the FoG

B.W. Fling, M. Mancini, P. Carlson-Kuhta, L.A. King, K. Smulders, D.S. Peterson, N. Pal, J.G. Nutt, F.B. Horak (Portland, OR, USA)

12:00pm-1:30pm

Patient satisfaction with flexible botulinum toxin injection intervals – Preliminary results of a telephone survey

C. Linder, S. Macher, E. Auff, T. Sycha (Vienna, Austria)

12:00pm-1:30pm

Randomized controlled trial protocol: Balance training with rhythmical cues to improve and maintain balance control in Parkinson’s disease

T.T.C. Capato, J. Tornai, V.F. Gianguiagi, R.R. Firmino, E.R. Barbosa, M.E. Piemonte (São Paulo, Brazil)

12:00pm-1:30pm

RE-024: A potential phosphopantothenate replacement therapy in 2 patients with pantothenate kinase-associated neurodegeneration (PKAN)

P. Roa, P. Stoeter, E. Perez, M. Santana (Santo Domingo, Dominican Republic)

12:00pm-1:30pm

RE-024: Mechanism of action and efficacy in non-clinical models

M. Beconi, E. Monteagudo, A. Di Marco, S. Malancona, D. Elbaum, S. Harper (San Diego, CA, USA)

12:00pm-1:30pm

Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations

C. Kenney, K. Kieburtz, W. Olanow, S. Bandak (San Francisco, CA, USA)

12:00pm-1:30pm

Risk factors for premature withdraw from the LS-1 PD study

J.Y. Fang, S. Luo, M. Huang, R.B. Dewey, R. Hauser, G. Chen (Nashville, TN, USA)

12:00pm-1:30pm

Sensor-based motor state detection in Parkinson’s disease to approach personalized therapy delivery

L.P. Roncoroni, M. Scholten, I. Hanci, A. Gharabagi, D. Weiss (Tübingen, Germany)

12:00pm-1:30pm

Significant improvement of adult-onset dystonia with cannabinoids-based oromucosal spray

M. Aguilar, S. Romero, L. Molina Porcel, P. Pastor (Terrassa, Spain)

12:00pm-1:30pm

STEADY-PD III. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease. Baseline characteristics of the enrolled cohort

T. Simuni, K.M. Biglan, J. Lowell, K. Hodgeman, B. Greco, R. Rockhill, D. Oakes (Chicago, IL, USA)

12:00pm-1:30pm

Strategies to improve drug development efficiency through regulatory interactions, minimizing the placebo effect and improving data integrity within a phase 3 study of tozadenant in Parkinson’s disease patients with motor fluctuations (TOZ-PD)

F. Kerwood, C. Kenney, K. Kieburtz, W. Olanow, C. Resburg, J. Krishnaswami, S. Bandak (San Francisco, CA, USA)

12:00pm-1:30pm

Systematic literature review of quetiapine for hallucinosis / psychosis in Parkinson’s disease (PD)

K. Dashtipour, J.J. Chen, L. Massihi, S. Tashiro, K. Frei (Loma Linda, CA, USA)

12:00pm-1:30pm

The effects of intensive speech treatment on intelligibility in Spanish dysarthria secondary to Parkinson’s disease

G. Moya-Gale, E. Levy (New York, NY, USA)

12:00pm-1:30pm

The systemic synuclein sampling study (S4)

D. Jennings, C. Coffey, T. Beach, T. Foroud, C.H. Adler, B. Mollenhauer, J. Seibyl, D. Ecklund, S. Lasch, V. Arnedo, C. Kopil (New Haven, CT, USA)

12:00pm-1:30pm

Therapeutic protocol for Parkinson’s patient with freezing based on action observation plus sonification: Preliminary results

S. Mezzarobba, M. Grassi, M. Catalan, L. Pellegrini, R. Valentini, B. Krüger, P. Manganotti, P. Bernardis (Trieste, Italy)

12:00pm-1:30pm

Utilizing remote blood pressure monitoring in a phase III clinical drug trial for Parkinson’s disease

J.L. Adams, R.A. Biemiller, K.L. Andrzejewski, S. Sharma, R.L. Rockhill, B.L. Greco, K.C. Hodgeman, P. Singh, S. Khanuja, T. Simuni, K.M. Biglan (Rochester, NY, USA)